Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chromosomal abnormalities are well-established biomarkers used in the subclassification and risk stratification of multiple myeloma patients. Patients with t(4;14)(p16;q32) and deletion 17p13 are considered to have a poor prognosis, and do not respond to any of the available therapies. However, most studies of chromosomal abnormalities incidence and risk stratification have been performed in patients younger than 66 years of age; therefore we have very limited data on the elderly population. This study was designed to uncover the incidence and clinical significance of 17p13 and 13q14 deletions and t(4;14) in a large cohort of clinically annotated multiple myeloma patients older than 66 years of age. Interestingly, the incidence of deletion of 13q14 and t(4;14) decreased with age, being significantly lower in patients >75 years old than in patients <75 years old. Conversely, the incidence of deletion 17p13 was not different between groups. Importantly, this study confirmed that t(4;14) and deletion 17p13 maintain a poor prognosis value in the elderly (66-75 years old) and the very elderly population (>75 years old), regardless of the treatment received.

Original languageEnglish (US)
Pages (from-to)1805-1808
Number of pages4
JournalFuture oncology (London, England)
Volume9
Issue number12
StatePublished - Dec 2013

Fingerprint

Multiple Myeloma
Chromosome Aberrations
Incidence
Biomarkers
Therapeutics
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{7931f1aba7584b208cd36546830a5a28,
title = "Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma.",
abstract = "Chromosomal abnormalities are well-established biomarkers used in the subclassification and risk stratification of multiple myeloma patients. Patients with t(4;14)(p16;q32) and deletion 17p13 are considered to have a poor prognosis, and do not respond to any of the available therapies. However, most studies of chromosomal abnormalities incidence and risk stratification have been performed in patients younger than 66 years of age; therefore we have very limited data on the elderly population. This study was designed to uncover the incidence and clinical significance of 17p13 and 13q14 deletions and t(4;14) in a large cohort of clinically annotated multiple myeloma patients older than 66 years of age. Interestingly, the incidence of deletion of 13q14 and t(4;14) decreased with age, being significantly lower in patients >75 years old than in patients <75 years old. Conversely, the incidence of deletion 17p13 was not different between groups. Importantly, this study confirmed that t(4;14) and deletion 17p13 maintain a poor prognosis value in the elderly (66-75 years old) and the very elderly population (>75 years old), regardless of the treatment received.",
author = "Braggio, {Esteban D}",
year = "2013",
month = "12",
language = "English (US)",
volume = "9",
pages = "1805--1808",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma.

AU - Braggio, Esteban D

PY - 2013/12

Y1 - 2013/12

N2 - Chromosomal abnormalities are well-established biomarkers used in the subclassification and risk stratification of multiple myeloma patients. Patients with t(4;14)(p16;q32) and deletion 17p13 are considered to have a poor prognosis, and do not respond to any of the available therapies. However, most studies of chromosomal abnormalities incidence and risk stratification have been performed in patients younger than 66 years of age; therefore we have very limited data on the elderly population. This study was designed to uncover the incidence and clinical significance of 17p13 and 13q14 deletions and t(4;14) in a large cohort of clinically annotated multiple myeloma patients older than 66 years of age. Interestingly, the incidence of deletion of 13q14 and t(4;14) decreased with age, being significantly lower in patients >75 years old than in patients <75 years old. Conversely, the incidence of deletion 17p13 was not different between groups. Importantly, this study confirmed that t(4;14) and deletion 17p13 maintain a poor prognosis value in the elderly (66-75 years old) and the very elderly population (>75 years old), regardless of the treatment received.

AB - Chromosomal abnormalities are well-established biomarkers used in the subclassification and risk stratification of multiple myeloma patients. Patients with t(4;14)(p16;q32) and deletion 17p13 are considered to have a poor prognosis, and do not respond to any of the available therapies. However, most studies of chromosomal abnormalities incidence and risk stratification have been performed in patients younger than 66 years of age; therefore we have very limited data on the elderly population. This study was designed to uncover the incidence and clinical significance of 17p13 and 13q14 deletions and t(4;14) in a large cohort of clinically annotated multiple myeloma patients older than 66 years of age. Interestingly, the incidence of deletion of 13q14 and t(4;14) decreased with age, being significantly lower in patients >75 years old than in patients <75 years old. Conversely, the incidence of deletion 17p13 was not different between groups. Importantly, this study confirmed that t(4;14) and deletion 17p13 maintain a poor prognosis value in the elderly (66-75 years old) and the very elderly population (>75 years old), regardless of the treatment received.

UR - http://www.scopus.com/inward/record.url?scp=84903666017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903666017&partnerID=8YFLogxK

M3 - Article

C2 - 24295409

AN - SCOPUS:84903666017

VL - 9

SP - 1805

EP - 1808

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 12

ER -